Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer Treatment
Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.
Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab. She says the drug was initially tested in both phase I and II trials, though the trials are being repeated to test margetuximab’s effectiveness on HER2-positive breast cancer.
Blackwell also says that if approved, margetuximab could benefit patients with HER2 over-expression that are not eligible for trastuzumab.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
